OXFORD, England, Dec. 13 /PRNewswire/ -- Chroma Therapeutics Limited, one of the UK's leading pre-IPO biotechnology companies, announced today positive data from a Phase I study with its oral, once-daily experimental cancer therapy CHR-2797 in the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and multiple myeloma (MM) who have failed on, or who are unsuitable for, chemotherapy.
Headline data from the study, which was presented by a key study
investigator, Dr. Faith Davies of the Royal Marsden Hospital, London, were
-- 3 out of 13 AML patients treated in this study showed a complete
response (CR) and one further AML patient became
-- one MM patient (out of two treated in this study) remained in stable
disease after six months of treatment with CHR-2797; and
-- the drug was very well-tolerated during the study
Chroma is currently assessing CHR-2797 in AML and MDS patients in the Phase II portion of this trial. This trial is now fully recruited and results are expected in the first half of 2008.
Ian Nicholson, Chief Executive Officer of Chroma, commented: "We are very encouraged by the efficacy we have seen in this Phase I study and look forward to further exploring how patients with this debilitating disease might be treated with CHR-2797".
An abstract of the data from this study was submitted to the recent
American Society of Hematology (ASH) meeting and was subsequently selected
for oral presentation. The full ASH presentation will be available at the
company's website, http://www.chromatherapeutics.com.
Chroma Therapeutics Limited
Ian Nicholson Chief Executive Officer +44 (0)1235 829120
Richard Bungay Chief Financial Officer
|SOURCE Chroma Therapeutics Limited|
Copyright©2007 PR Newswire.
All rights reserved